细胞保护性3K3A-活化蛋白C与血浆:创伤内皮病的治疗比较
本研究采用电细胞-基底阻抗传感(ECIS)实时测量内皮细胞通透性变化,比较3K3A-aPC与血浆对创伤内皮病(EoT)的体外效果。细胞在严重创伤患者血浆(ISS>15且BD<-6)刺激前30分钟接受2 μg/mL aPC处理,或同时加入健康血浆/FP24。结果发现,5%血浆浓度下同时加入3K3A-aPC较单用创伤血浆改善通透性(μd 10.11,95%CI 2.642-17.57),而10%浓度无差异;3K3A-aPC预处理组的细胞间通透性低于3K3A-aPC+血浆+创伤血浆联合组。作者认为3K3A-aPC预处理可能更大程度减轻EoT,但需进一步探索。
要点
- 体外ECIS实验中,5%血浆浓度下同时加入3K3A-aPC较单用创伤血浆改善内皮通透性(μd 10.11,95%CI 2.642-17.57)。
- 10%血浆浓度下同时加入3K3A-aPC与单用创伤血浆无差异(μd -1.394,95%CI -8.859至6.070)。
- 3K3A-aPC+血浆+创伤血浆联合组在5%血浆浓度(μd -28.52,95%CI -34.72至-22.32)和10%血浆浓度(μd -40.02,95%CI -46.22至-33.82)下细胞间通透性均高于3K3A-aPC预处理组。
- 5%与10%血浆处理组之间存在剂量依赖性差异(μd 7.346,95%CI 4.574-10.12)。
- 作者认为3K3A-aPC预处理可能比FP24单用或联用3K3A-aPC更大程度减轻EoT,但需进一步探索。
适用人群与场景
- 体外实验,使用人脐静脉内皮细胞(HUVEC)
- 创伤血浆取自严重创伤患者,纳入标准为ISS>15且BD<-6
- 对照包括凝血酶处理细胞和未处理细胞
诊断标准与关键阈值
- 严重创伤患者血浆定义:ISS>15且BD<-6
处置流程与药物剂量
- 细胞以2 μg/mL的aPC溶液预处理30分钟,再接受创伤血浆刺激
- 健康血浆或24小时内冷冻血浆(FP24)与创伤血浆同时加入
- 血浆浓度分为5%和10%两组
研究设计与关键结果
- 研究类型为体外细胞实验,采用电细胞-基底阻抗传感(ECIS)实时测量内皮细胞通透性变化。
- 5%与10%血浆处理组在创伤血浆同时刺激HUVEC时存在剂量依赖性差异(μd 7.346;95%CI 4.574-10.12)。
- 5%血浆组与单用创伤血浆比较无差异(μd 5.713;95%CI -1.751至13.18);10%血浆组与单用创伤血浆比较无差异(μd -1.633;95%CI -9.097至5.832)。
- 3K3A-aPC+血浆+创伤血浆时,5%血浆组较单用创伤血浆通透性改善(μd 10.11;95%CI 2.642-17.57);10%血浆组无差异(μd -1.394;95%CI -8.859至6.070)。
- 3K3A-aPC+血浆+创伤血浆联合组在5%血浆浓度(μd -28.52;95%CI -34.72至-22.32)和10%血浆浓度(μd -40.02;95%CI -46.22至-33.82)下细胞间通透性均高于3K3A-aPC预处理组。
证据类型、等级与局限
- 证据类型:体外细胞实验。
- 局限:作者指出需要进一步探索。
对床旁实践的改变
- 作者认为,在创伤后环境中,3K3A-aPC预处理可能比FP24单用或FP24联用3K3A-aPC更大程度减轻EoT,可能成为创伤患者失调性血栓炎症的潜在理想且或许更优的治疗。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Both healthy plasma and cytoprotective aPC (3K3A-aPC) have been shown to mitigate the endotheliopathy of trauma (EoT), but optimal therapeutics remain unknown. Our aim was therefore to determine optimal therapies to mitigate EoT by investigating the effectiveness of 3K3A-aPC with and without plasma-based resuscitation strategies.
METHODS: Electric cell-substrate impedance sensing (ECIS) was used to measure real-time permeability changes in endothelial cells. Cells were treated with a 2-μg/mL solution of aPC 30 minutes prior to stimulation with plasma taken from severely injured trauma patients (ISS > 15 and BD < -6) (TP). Healthy plasma, or plasma frozen within 24 hours (FP24), was added concomitantly with TP. Cells treated with thrombin and untreated cells were included in this study as control groups.
RESULTS: A dose-dependent difference was found between the 5% and 10% plasma-treated groups when human umbilical vein endothelial cells were simultaneously stimulated with TP (μd, 7.346; 95% confidence interval [CI], 4.574-10.12). There was no difference when compared with TP alone in the 5% (μd, 5.713; 95% CI, -1.751 to 13.18) or 10% group (μd, -1.633; 95% CI, -9.097 to 5.832). When 3K3A-aPC was added to plasma and TP, the 5% group showed improvement in permeability compared with TP alone (μd, 10.11; 95% CI, 2.642 to 17.57), but there was no difference in the 10% group (μd -1.394; 95% CI, -8.859 to 6.070). The combination of 3K3A-aPC, plasma, and TP at both the 5% plasma (μd, -28.52; 95% CI, -34.72 to -22.32) and 10% plasma concentrations (μd, -40.02; 95% CI, -46.22 to -33.82) had higher intercellular permeability than the 3K3A-aPC preincubation group.
CONCLUSION: Our data show that FP24, in a posttrauma environment, pretreatment with 3K3A-aPC can potentially mitigate the EoT to a greater degree than FP24 with or without 3K3A-aPC. Although further exploration is needed, this represents a potentially ideal and perhaps superior therapeutic treatment for the dysregulated thromboinflammation of injured patients.
参考来源
- Thielen O, Stafford P, Debot M, et al. Cytoprotective 3K3A-activated protein C and plasma: A comparison of therapeutics for the endotheliopathy of trauma. J Trauma Acute Care Surg. 2024. PMID: 38797883. doi:10.1097/TA.0000000000004406
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。